US Stock MarketDetailed Quotes

VALN Valneva

Watchlist
  • 4.790
  • -0.340-6.63%
Close Nov 12 16:00 ET
388.88MMarket Cap-9392P/E (TTM)
Pre-Market
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Chad Dunbar
    Chad Dunbar
    Oct 31 14:42
    Vaccine that nobody is talking about has potential…
    $Valneva (VALN.US)$
    I notice that when people talk about Valneva, you hear endless talk about Lyme & Chikungunya, but there is almost no talk about SV4, a tetravalent bioconjugate vaccine candidate against shigellosis that is entering Phase 2. It seems that most of the talk regarding this centers around children in third world underdeveloped countries, but there is a possible huge market if it gets worked into the standard childhood vaccine sched...
    Trytosaveabit
    Trytosaveabit
    Sep 3 08:15
    Update
    $Valneva (VALN.US)$ Pfizer, Valneva Report Further Positive Phase 2 Booster Results For Lyme Disease Vaccine Candidate
    Drug makers Pfizer Inc. (PFE) and Valneva SE (VALN) announced Tuesday positive immunogenicity and safety data from their VLA15-221 Phase 2 study following a second booster vaccination of their Lyme disease vaccine candidate, VLA15, given one year after receiving the first booster dose.
    Pfizer aims to submit a Biologics License Application or BLA to the U.S. Food and Drug Ad...
    Trytosaveabit
    Trytosaveabit
    Jul 22 05:30
    News
    $Valneva (VALN.US)$ Valneva is set to receive up to $41.3 million from CEPI and the EU to enhance access to IXCHIQ®, the world’s first chikungunya vaccine, particularly in low- and middle-income countries. The funding will bolster clinical trials in vulnerable groups and support technology transfer to additional manufacturers, ensuring wider distribution in regions at risk of chikungunya outbreaks. With approvals already in place in the U.S., Canada, and Europe, the company aims to extend the...
    2
    Trytosaveabit
    Trytosaveabit
    Jun 28 07:32
    Update
    $Valneva (VALN.US)$ Valneva's Chikungunya Vaccine Secures Approval for Use in EU
    MT Newswires· 4 mins ago
    Trytosaveabit
    Trytosaveabit
    May 13 03:44
    Update
    $Valneva (VALN.US)$ Results Intended to Support Filing for Potential Label Extension for Use in Adolescents Saint-Herblain (France), May 13, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today reported further positive pivotal Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine. Following the initial analysis up to Day 29 post-vaccination, the most recent analysis of study VLA1553-321 evaluated the safety and immunogenicity six months...
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data